First Header Logo Second Header Logo

Connection

Elsayed Soliman to Hypertrophy, Left Ventricular

Back to Details
This is a "connection" page, showing publications Elsayed Soliman has written about Hypertrophy, Left Ventricular.
Elsayed Soliman
Connection Strength
13.327
Hypertrophy, Left Ventricular
  1. Soliman EZ, Mills KT. Exploring the Relationship Between Intensive Blood Pressure Lowering, Left Ventricular Hypertrophy, and Cardiovascular Outcomes. Hypertension. 2023 Sep; 80(9):1843-1844.
    View in: PubMed
    Score: 0.832
  2. Ahmad MI, Mujtaba M, Anees MA, Li Y, Soliman EZ. Interrelation Between Electrocardiographic Left Atrial Abnormality, Left Ventricular Hypertrophy, and Mortality in Participants With Hypertension. Am J Cardiol. 2019 09 15; 124(6):886-891.
    View in: PubMed
    Score: 0.625
  3. Sparapani R, Dabbouseh NM, Gutterman D, Zhang J, Chen H, Bluemke DA, Lima JAC, Burke GL, Soliman EZ. Detection of Left Ventricular Hypertrophy Using Bayesian Additive Regression Trees: The MESA. J Am Heart Assoc. 2019 03 05; 8(5):e009959.
    View in: PubMed
    Score: 0.612
  4. Cao X, Broughton ST, Waits GS, Nguyen T, Li Y, Soliman EZ. Interrelations Between Hypertension and Electrocardiographic Left Ventricular Hypertrophy and Their Associations With Cardiovascular Mortality. Am J Cardiol. 2019 01 15; 123(2):274-283.
    View in: PubMed
    Score: 0.596
  5. Ahmad MI, Li Y, Soliman EZ. Association of obesity phenotypes with electrocardiographic left ventricular hypertrophy in the general population. J Electrocardiol. 2018 Nov - Dec; 51(6):1125-1130.
    View in: PubMed
    Score: 0.595
  6. Soliman EZ, Ambrosius WT, Lewis CE. Response by Soliman et al to Letters Regarding Article, "Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial)". Circulation. 2018 03 20; 137(12):1300-1301.
    View in: PubMed
    Score: 0.572
  7. Soliman EZ, Prineas RJ. Antihypertensive Therapies and Left Ventricular Hypertrophy. Curr Hypertens Rep. 2017 Sep 19; 19(10):79.
    View in: PubMed
    Score: 0.553
  8. Soliman EZ, Ambrosius WT, Cushman WC, Zhang ZM, Bates JT, Neyra JA, Carson TY, Tamariz L, Ghazi L, Cho ME, Shapiro BP, He J, Fine LJ, Lewis CE. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017 Aug 01; 136(5):440-450.
    View in: PubMed
    Score: 0.540
  9. Patel N, O'Neal WT, Whalen SP, Soliman EZ. Electrocardiographic left ventricular hypertrophy predicts atrial fibrillation independent of left ventricular mass. Ann Noninvasive Electrocardiol. 2017 May; 22(3):1-5.
    View in: PubMed
    Score: 0.525
  10. Oseni AO, Qureshi WT, Almahmoud MF, Bertoni AG, Bluemke DA, Hundley WG, Lima JA, Herrington DM, Soliman EZ. Left ventricular hypertrophy by ECG versus cardiac MRI as a predictor for heart failure. Heart. 2017 01 01; 103(1):49-54.
    View in: PubMed
    Score: 0.511
  11. Leigh JA, O'Neal WT, Soliman EZ. Electrocardiographic Left Ventricular Hypertrophy as a Predictor of Cardiovascular Disease Independent of Left Ventricular Anatomy in Subjects Aged =65 Years. Am J Cardiol. 2016 Jun 01; 117(11):1831-5.
    View in: PubMed
    Score: 0.498
  12. O'Neal WT, Howard VJ, Kleindorfer D, Kissela B, Judd SE, McClure LA, Cushman M, Howard G, Soliman EZ. Interrelationship between electrocardiographic left ventricular hypertrophy, QT prolongation, and ischaemic stroke: the REasons for Geographic and Racial Differences in Stroke Study. Europace. 2016 May; 18(5):767-72.
    View in: PubMed
    Score: 0.484
  13. Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC, Chen H. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension. 2015 Dec; 66(6):1123-9.
    View in: PubMed
    Score: 0.483
  14. Estes EH, Zhang ZM, Li Y, Tereshchenko LG, Soliman EZ. Individual components of the Romhilt-Estes left ventricular hypertrophy score differ in their prediction of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015 Dec; 170(6):1220-6.
    View in: PubMed
    Score: 0.482
  15. O'Neal WT, Almahmoud MF, Qureshi WT, Soliman EZ. Electrocardiographic and Echocardiographic Left Ventricular Hypertrophy in the Prediction of Stroke in the Elderly. J Stroke Cerebrovasc Dis. 2015 Sep; 24(9):1991-7.
    View in: PubMed
    Score: 0.474
  16. Almahmoud MF, O'Neal WT, Qureshi W, Soliman EZ. Electrocardiographic Versus Echocardiographic Left Ventricular Hypertrophy in Prediction of Congestive Heart Failure in the Elderly. Clin Cardiol. 2015 Jun; 38(6):365-70.
    View in: PubMed
    Score: 0.469
  17. Estes EH, Zhang ZM, Li Y, Tereschenko LG, Soliman EZ. The Romhilt-Estes left ventricular hypertrophy score and its components predict all-cause mortality in the general population. Am Heart J. 2015 Jul; 170(1):104-9.
    View in: PubMed
    Score: 0.467
  18. Bacharova L, Chen H, Estes EH, Mateasik A, Bluemke DA, Lima JA, Burke GL, Soliman EZ. Determinants of discrepancies in detection and comparison of the prognostic significance of left ventricular hypertrophy by electrocardiogram and cardiac magnetic resonance imaging. Am J Cardiol. 2015 Feb 15; 115(4):515-22.
    View in: PubMed
    Score: 0.455
  19. Rautaharju PM, Soliman EZ. Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: a critical appraisal. J Electrocardiol. 2014 Sep-Oct; 47(5):649-54.
    View in: PubMed
    Score: 0.440
  20. Soliman EZ, Shah AJ, Boerkircher A, Li Y, Rautaharju PM. Inter-relationship between electrocardiographic left ventricular hypertrophy and QT prolongation as predictors of increased risk of mortality in the general population. Circ Arrhythm Electrophysiol. 2014 Jun; 7(3):400-6.
    View in: PubMed
    Score: 0.437
  21. Bacharova L, Chevalier P, Gorenek B, Jons C, Li YG, Locati ET, Maanja M, Pérez-Riera AR, Platonov PG, Ribeiro ALP, Schocken D, Soliman EZ, Svehlikova J, Tereshchenko LG, Ugander M, Varma N, Elena Z, Ikeda T. ISE/ISHNE expert consensus statement on the ECG diagnosis of left ventricular hypertrophy: The change of the paradigm. Ann Noninvasive Electrocardiol. 2024 Jan; 29(1):e13097.
    View in: PubMed
    Score: 0.212
  22. Ahmad MI, Kazibwe R, Soliman MZ, Singh S, Chen LY, Soliman EZ. Joint Association of Albuminuria and Left Ventricular Hypertrophy With Incident Heart Failure in Adults at High Risk With Hypertension: A Systolic Blood Pressure Intervention Trial Substudy. Am J Cardiol. 2023 Dec 01; 208:75-82.
    View in: PubMed
    Score: 0.210
  23. Bacharova L, Chevalier P, Gorenek B, Jons C, Li YG, Locati ET, Maanja M, Pérez-Riera AR, Platonov PG, Ribeiro ALP, Schocken D, Soliman EZ, Svehlikova J, Tereshchenko LG, Ugander M, Varma N, Zaklyazminskaya E, Ikeda T. ISE/ISHNE Expert Consensus Statement on ECG Diagnosis of Left Ventricular Hypertrophy: The Change of the Paradigm. The joint paper of the International Society of Electrocardiology and the International Society for Holter Monitoring and Noninvasive Electrocardiology. J Electrocardiol. 2023; 81:85-93.
    View in: PubMed
    Score: 0.208
  24. Afify H, Lee HL, Soliman EZ, Singleton MJ. Prognostic significance of body mass index-adjusted criteria for left ventricular hypertrophy. J Clin Hypertens (Greenwich). 2020 08; 22(8):1476-1483.
    View in: PubMed
    Score: 0.169
  25. Meyer ML, Soliman EZ, Drager D, Heiss G. Short-term repeatability of electrocardiographic criteria of left ventricular hypertrophy. Ann Noninvasive Electrocardiol. 2020 03; 25(2):e12688.
    View in: PubMed
    Score: 0.158
  26. Brooks JE, Soliman EZ, Upadhya B. Is Left Ventricular Hypertrophy a Valid Therapeutic Target? Curr Hypertens Rep. 2019 05 20; 21(6):47.
    View in: PubMed
    Score: 0.155
  27. Norby FL, Chen LY, Soliman EZ, Gottesman RF, Mosley TH, Alonso A. Association of left ventricular hypertrophy with cognitive decline and dementia risk over 20 years: The Atherosclerosis Risk In Communities-Neurocognitive Study (ARIC-NCS). Am Heart J. 2018 10; 204:58-67.
    View in: PubMed
    Score: 0.147
  28. Brinkley TE, Anderson A, Soliman EZ, Bertoni AG, Greenway F, Knowler WC, Glasser SP, Horton ES, Espeland MA. Long-Term Effects of an Intensive Lifestyle Intervention on Electrocardiographic Criteria for Left Ventricular Hypertrophy: The Look AHEAD Trial. Am J Hypertens. 2018 04 13; 31(5):541-548.
    View in: PubMed
    Score: 0.144
  29. Bang CN, Soliman EZ, Simpson LM, Davis BR, Devereux RB, Okin PM. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. Am J Hypertens. 2017 Sep 01; 30(9):914-922.
    View in: PubMed
    Score: 0.138
  30. Bacharova L, Estes HE, Schocken DD, Ugander M, Soliman EZ, Hill JA, Bang LE, Schlegel TT. The 4th Report of the Working Group on ECG diagnosis of Left Ventricular Hypertrophy. J Electrocardiol. 2017 Jan - Feb; 50(1):11-15.
    View in: PubMed
    Score: 0.130
  31. Ernst ME, Davis BR, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, Cushman WC, Einhorn PT, Oparil S, Grimm RH. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Am Soc Hypertens. 2016 12; 10(12):930-938.e9.
    View in: PubMed
    Score: 0.130
  32. Okwuosa TM, Soliman EZ, Lopez F, Williams KA, Alonso A, Ferdinand KC. Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am Heart J. 2015 Jan; 169(1):155-61.e5.
    View in: PubMed
    Score: 0.113
  33. Chrispin J, Jain A, Soliman EZ, Guallar E, Alonso A, Heckbert SR, Bluemke DA, Lima JA, Nazarian S. Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014 May 20; 63(19):2007-13.
    View in: PubMed
    Score: 0.108
  34. Agarwal SK, Soliman EZ. ECG abnormalities and stroke incidence. Expert Rev Cardiovasc Ther. 2013 Jul; 11(7):853-61.
    View in: PubMed
    Score: 0.103
  35. Ernst ME, Neaton JD, Grimm RH, Collins G, Thomas W, Soliman EZ, Prineas RJ. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011 Dec; 58(6):1001-7.
    View in: PubMed
    Score: 0.092
  36. Zhang ZM, Prineas RJ, Soliman EZ, Baggett C, Heiss G. Prognostic significance of serial Q/ST-T changes by the Minnesota Code and Novacode in the Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2012 Dec; 19(6):1430-6.
    View in: PubMed
    Score: 0.092
  37. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011 Nov; 121(11):4393-408.
    View in: PubMed
    Score: 0.092
  38. Jain A, Tandri H, Dalal D, Chahal H, Soliman EZ, Prineas RJ, Folsom AR, Lima JA, Bluemke DA. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2010 Apr; 159(4):652-8.
    View in: PubMed
    Score: 0.082
  39. Ascher SB, de Lemos JA, Lee M, Wu E, Soliman EZ, Neeland IJ, Kitzman DW, Ballantyne CM, Nambi V, Killeen AA, Ix JH, Shlipak MG, Berry JD. Intensive Blood Pressure Lowering in Patients With Malignant Left Ventricular Hypertrophy. J Am Coll Cardiol. 2022 Oct 18; 80(16):1516-1525.
    View in: PubMed
    Score: 0.049
  40. Garg PK, O'Neal WT, Ogunsua A, Thacker EL, Howard G, Soliman EZ, Cushman M. Usefulness of the American Heart Association's Life Simple 7 to Predict the Risk of Atrial Fibrillation (from the REasons for Geographic And Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2018 01 15; 121(2):199-204.
    View in: PubMed
    Score: 0.035
  41. Alburikan KA, Aldemerdash A, Savitz ST, Tisdale JE, Whitsel EA, Soliman EZ, Thudium EM, Sueta CA, Kucharska-Newton AM, Stearns SC, Rodgers JE. Contribution of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) study. J Eval Clin Pract. 2017 Dec; 23(6):1274-1280.
    View in: PubMed
    Score: 0.034
  42. McClure LA, Kleindorfer DO, Kissela BM, Cushman M, Soliman EZ, Howard G. Assessing the performance of the Framingham Stroke Risk Score in the reasons for geographic and racial differences in stroke cohort. Stroke. 2014 Jun; 45(6):1716-20.
    View in: PubMed
    Score: 0.027
  43. Carnethon MR, Ning H, Soliman EZ, Lewis CE, Schreiner PJ, Sidney S, Lloyd-Jones DM. Association of electrocardiographically determined left ventricular mass with incident diabetes, 1985-1986 to 2010-2011: Coronary Artery Risk Development in Young Adults (CARDIA) study. Diabetes Care. 2013 Mar; 36(3):645-7.
    View in: PubMed
    Score: 0.025
  44. Prineas RJ, Le A, Soliman EZ, Zhang ZM, Howard VJ, Ostchega Y, Howard G. United States national prevalence of electrocardiographic abnormalities in black and white middle-age (45- to 64-Year) and older (=65-Year) adults (from the Reasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2012 Apr 15; 109(8):1223-8.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.